Mark L. Baum is the Chairman of the Board and CEO of NASDAQ-listed Harrow Health, an eyecare-focused pharmaceuticals business, which he founded in 2012. For the 2014-2017 periods, Harrow (formerly Imprimis Pharmaceuticals) was named by Deloitte’s Technology Fast 500™ as one of the fastest growing companies in North America. Mr. Baum is also a founder and former board member of Eton Pharmaceuticals (NASDAQ: ETON) and Melt Pharmaceuticals and is a founder and board member of Surface Ophthalmics. From 2014-2017, Mr. Baum served as a senior advisor to Curology.com. Prior to Harrow, as the founder of TBLF, LLC, a private investment fund manager, Mr. Baum made more than 200 investments into more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum’s advocacy for drug pricing and patient and physician accessibility issues has been featured in Op-Ed contributions for the Wall Street Journal and through television appearances on leading national media outlets. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Mr. Baum is a graduate, cum laude, of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.